share_log

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Adjusts Price Target To $10

Benzinga ·  Jan 8 06:22

HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Buy, adjusts target to $10 from $1.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment